Neurodegenerative disease and cancer: Two sides of a coin?

Hospital Practice

Volumn 36, Issue 9, 2001, Pages 39-45

  Bredesen, Dale E ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANDROGEN RECEPTOR; ATAXIN 2; ATAXIN 3; ATROPHIN 1; CASPASE; GENE PRODUCT; HUNTINGTIN; PRESENILIN 1; PRESENILIN 2; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; APOPTOSIS; CELL DEATH; CELL DISRUPTION; CLINICAL FEATURE; DEGENERATIVE DISEASE; GENETIC ANALYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; ONSET AGE; RECEPTOR GENE; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035885907     PISSN: 87502836     EISSN: None     Source Type: Journal    
DOI: 10.1080/21548331.2001.11444144     Document Type: Review

References (8)

1. NTR and the concept of cellular dependence: Seeing how the other half die
2. Anti-cancer activity of targeted pro-apoptotic peptides
3. Cleavage of atrophin-I AT caspase site asparatic acid 109 modulates cytotoxicity
4. Kennedy's disease: Caspase cleavage of the androgen receptor is a crucial event in cytotoxicity
5. A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor
6. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis
7. Induction of apoptosis by the low-affinity NGF receptor
8. An alternative, nonapoptotic form of programmed cell death